Find Reports
Select Report Type
Reimbursement Review
Displaying 276 - 300 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Inrebic | fedratinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | PC0205-000 | |||
| Ilumya | tildrakizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | SR0624-000 | |||
| Rybelsus | semaglutide | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0637-000 | |||
| Reblozyl | luspatercept | beta-thalassemia associated anemia | Reimburse with clinical criteria and/or conditions | Complete | SR0669-000 | |||
| Dupixent | dupilumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | SR0667-000 | |||
| Veltassa | patiromer | Hyperkalemia, adults (chronic kidney disease) | Reimburse with clinical criteria and/or conditions | Complete | SR0665-000 | |||
| Tafinlar and Mekinist | Dabrafenib and Trametinib |
Dabrafenib-Trametinib NSCLC BRAF V600 – pERC Final RecommandationDabrafenib-Trametinib NSCLC BRAF V600 – Final Economic Guidance ReportDabrafenib-Trametinib NSCLC BRAF V600 – Final Clinical Guidance ReportDabrafenib-Trametinib NSCLC BRAF V600 – PAG Feedback on Initial RecommendationDabrafenib-Trametinib NSCLC BRAF V600 – Manufacturer Feedback on Initial Recomm…Dabrafenib-Trametinib NSCLC BRAF V600 – Patient Advocacy Group Feedback on Init…Dabrafenib-Trametinib NSCLC BRAF V600 – Clinician Feedback on Initial Recommend…Dabrafenib-Trametinib NSCLC BRAF V600 – Patient Advocacy Group COI Declarations Dabrafenib-Trametinib NSCLC BRAF V600 – Clinician COI Declarations |
NSCLC BRAF V600 | Reimburse with clinical criteria and/or conditions | Complete | PC0226-000 | ||
| Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete | SR0655-000 | |||
| Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete | PC0215-000 | |||
| Zejula | Niraparib | First Line OC | Reimburse with clinical criteria and/or conditions | Complete | PC0224-000 | |||
| Remsima | infliximab | Rheumatoid arthritis | Reimburse with clinical criteria and/or conditions | Complete | SR0659-000 | |||
| Enspryng | satralizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | SR0663-000 | |||
| Polivy | Polatuzumab Vedotin | Diffuse large B-cell lymphoma (DLBCL) | Reimburse with clinical criteria and/or conditions | Complete | PC0227-000 | |||
| Alunbrig | Brigatinib | (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | PC0230-000 | |||
| Lynparza | Olaparib | metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0223-000 | |||
| Ruzurgi | amifampridine | Lambert-Eaton myasthenic syndrome | Reimburse with clinical criteria and/or conditions | Complete | SR0660-000 | |||
| Sarclisa | Isatuximab | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | PC0220-000 | |||
| Entresto | sacubitril/valsartan | Heart failure, NYHA Class II or III | Reimburse with clinical criteria and/or conditions | Complete | SR0644-000 | |||
| Ajovy | fremanezumab | migraine | Reimburse with clinical criteria and/or conditions | Complete | SR0641-000 | |||
| Zolgensma | onasemnogene abeparvovec | Spinal muscular atrophy (SMA), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | SG0649-000 | |||
| Bavencio | Avelumab | Urothelial Carcinoma (UC) | Reimburse with clinical criteria and/or conditions | Complete | PC0225-000 | |||
| Vonvendi | von Willebrand Factor [recombinant] | von Willebrand disease, adults, treatment and perioperative management | Reimburse with clinical criteria and/or conditions | Complete | ST0639-000 | |||
| Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | NSCLC | Reimburse with clinical criteria and/or conditions | Complete | PC0218-000 | |||
| Kesimpta | ofatumumab | Multiple Sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | SR0657-000 | |||
| Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | SR0650-000 |
Health Technology Review
Displaying 276 - 300 of 589
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 276 - 300 of 2093
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Large B cell lymphoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0048-000 | |||
| Cutaneous Melanoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0049-000 | |||
| Multiple Myeloma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0047-000 | |||
| Drug Shortages in Canada | Health Technology Review | Environmental Scan | Completed | ES0381-000 | |||
| sotorasib | Reimbursement Review | Complete | PC0300-000 | ||||
| drospirenone | Reimbursement Review | Complete | SR0806-000 | ||||
| dostarlimab | Reimbursement Review | Complete | PC0325-000 | ||||
| Pharmaceutical Reviews Update — Issue 49 | Reimbursement Review | Pharmaceutical Review Update | |||||
| solriamfetol | Reimbursement Review | Not filed | NS0039-000 | ||||
| solriamfetol | Reimbursement Review | Not filed | NS0038-000 | ||||
| zanubrutinib | Reimbursement Review | Not filed | NS0037-000 | ||||
| pembrolizumab | Reimbursement Review | Not filed | NS0034-000 | ||||
| trastuzumab deruxtecan | Reimbursement Review | Not filed | NS0035-000 | ||||
| capmatinib | Reimbursement Review | Not filed | NS0036-000 | ||||
| daratumumab | Reimbursement Review | Not filed | NS0031-000 | ||||
| liraglutide | Reimbursement Review | Not filed | NS0032-000 | ||||
| dexamethasone intravitreal implant | Reimbursement Review | Not filed | NS0033-000 | ||||
| dabrafenib and trametinib | Reimbursement Review | Not filed | NS0029-000 | ||||
| treosulfan | Reimbursement Review | Not filed | NS0030-000 | ||||
| omalizumab | Reimbursement Review | Not filed | NS0026-000 | ||||
| mepolizumab | Reimbursement Review | Not filed | NS0027-000 | ||||
| dabrafenib and trametinib | Reimbursement Review | Not filed | NS0028-000 | ||||
| sofosbuvir / velpatasvir | Reimbursement Review | Not filed | NS0024-000 | ||||
| fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | Reimbursement Review | Not filed | NS0025-000 | ||||
| Rivaroxaban (granules for oral suspension) | Reimbursement Review | Not filed | NS0022-000 |